Recent FDA approval of front - line brentuximab vedotin with chemotherapy in patients with stage III / IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years. (cancernetwork.com)
«Five - year survival data: Brentuximab vedotin may be curative in some with Hodgkin lymphoma: Phase II trial suggests therapy should be standard of care for patients facing relapsed or treatment - resistant Hodgkin lymphoma.» (sciencedaily.com)
«The FDA Breakthrough Therapy designation underscores the potential of enfortumab vedotin as a meaningful treatment for patients with locally advanced or metastatic urothelial cancer,» said Robert Lechleider, MD, the vice president of clinical development at Seattle Genetics, according to a press release. (cancernetwork.com)